Drug combinations for the treatment of duchenne muscular dystrophy

Abstract

Combinations comprising (or consisting essentially of) one or more compounds of formula (1) with one or more ancillary agents, to processes for preparing the combinations, and to various therapeutic uses of the combinations. Also provided are pharmaceutical compositions containing the combinations as well as a method of treatment of Duchenne muscular dystrophy, Becker muscular dystrophy or cachexia using the combinations.

1 - 53 . (canceled) 
     
     
         54 . A method for the treatment of a disorder selected from Duchenne muscular dystrophy, Becker muscular dystrophy, and cachexia, comprising administering to a patient that has been diagnosed with said disorder an effective amount of:
 a) the compound 5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole, or a pharmaceutically acceptable salt thereof, wherein said patient is undergoing treatment with a corticosteroid;   b) a corticosteroid, wherein said patient is undergoing treatment with the compound 5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole, or a pharmaceutically acceptable salt thereof; or   c) a combination of the compound 5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole, or a pharmaceutically acceptable salt thereof, and a corticosteroid.   
     
     
         55 . A method according to  claim 54 , wherein said method comprises administering to a patient the compound 5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole, or a pharmaceutically acceptable salt thereof, wherein said patient is undergoing treatment with a corticosteroid. 
     
     
         56 . A method according to  claim 54 , wherein said method comprises administering to a patient a corticosteroid, wherein said patient is undergoing treatment with the compound 5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole, or a pharmaceutically acceptable salt thereof. 
     
     
         57 . A method according to  claim 54 , wherein said method comprises administering to a patient the combination of the compound 5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole, or a pharmaceutically acceptable salt thereof, and a corticosteroid to a patient. 
     
     
         58 . The method of  claim 57  wherein the corticosteroid and the compound 5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole, or a pharmaceutically acceptable salt thereof, are physically associated; or the corticosteroid and the compound 5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole, or a pharmaceutically acceptable salt thereof, are non-physically associated; or the corticosteroid and the compound 5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole, or a pharmaceutically acceptable salt thereof, are
 a) in admixture; 
 b) chemically/physicochemically linked; 
 c) chemically/physicochemically co-packaged; or 
 d) unmixed but co-packaged or co-presented. 
 
     
     
         59 . The method of  claim 58  wherein the corticosteroid and the compound 5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole, or a pharmaceutically acceptable salt thereof, are administered sequentially. 
     
     
         60 . The method of  claim 58  wherein the corticosteroid and the compound 5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole, or a pharmaceutically acceptable salt thereof, are administered simultaneously. 
     
     
         61 . The method of  claim 60  wherein the corticosteroid and the compound 5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole, or a pharmaceutically acceptable salt thereof, are administered simultaneously in a unitary formulation. 
     
     
         62 . The method of  claim 60  wherein the corticosteroid and the compound 5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole, or a pharmaceutically acceptable salt thereof, are administered simultaneously in different pharmaceutical formulations. 
     
     
         63 . The method according to  claim 54  wherein the corticosteroid is selected from prednisone, prednisolone, and deflazacort. 
     
     
         64 . The method according to  claim 54 , wherein said disorder is Duchenne muscular dystrophy. 
     
     
         65 . The method according to  claim 54 , wherein said disorder is Becker muscular dystrophy. 
     
     
         66 . The method according to  claim 54 , wherein said disorder is cachexia. 
     
     
         67 . The method according to  claim 54 , wherein said compound 5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole, or a pharmaceutically acceptable salt thereof, is in admixture with a pharmaceutically acceptable diluent or carrier. 
     
     
         68 . A method for the treatment of a disorder selected from Duchenne muscular dystrophy, Becker muscular dystrophy, and cachexia, comprising administering to a patient that has been diagnosed with said disorder an effective amount of the compound 5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole, or a pharmaceutically acceptable salt thereof, and a corticosteroid; wherein said 5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole, or a pharmaceutically acceptable salt thereof, is administered before, after, or at the same time as said corticosteroid. 
     
     
         69 . The method according to  claim 68 , wherein said 5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole, or a pharmaceutically acceptable salt thereof, is administered before said corticosteroid. 
     
     
         70 . The method according to  claim 68 , wherein said 5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole, or a pharmaceutically acceptable salt thereof, is administered after said corticosteroid. 
     
     
         71 . The method according to  claim 68 , wherein said 5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole, or a pharmaceutically acceptable salt thereof, is administered at the same time as said corticosteroid. 
     
     
         72 . The method of  claim 71  wherein the corticosteroid and the compound 5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole, or a pharmaceutically acceptable salt thereof, are administered simultaneously in a unitary formulation. 
     
     
         73 . The method of  claim 71  wherein the corticosteroid and the compound 5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole, or a pharmaceutically acceptable salt thereof, are administered simultaneously in different pharmaceutical formulations.